IP Library Granted Patent US 8,563,597
Granted Patent B2
US 8,563,597 · App. 13/819,141 · Granted Oct 22, 2013

Fused tricyclic ether carbamates and their use

Inventors: Arun K. Ghosh (West Lafayette, IN); Chun-Xiao Xu (College Station, TX); Hiroaki Mitsuya (Kumamoto, JP); Garth Parham (Largo, FL)
Assignees: Purdue Research Foundation; National University Corporation Kumamoto University
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,563,597
App. No.
13/819,141
Granted
Oct 22, 2013
Kind
B2
Abstract

Tricylic ether carbamates that inhibit HIV proteolytic enzymes and processes for preparing the compounds are described. Methods of using the disclosed compounds for treating patients infected with HIV are also described.

Claims (42)

1. A compound of the formula

or a pharmaceutically acceptable salt thereof, wherein

X 1 is a bond or optionally substituted alkylene;

X 2 is a bond, C(O), S(O), S(O) 2 , optionally substituted amino, or optionally substituted alkylene;

R 1 and R 2 are in each instance independently selected from the group consisting of hydrogen, P(O)(OR) 2 , and a prodrug forming group, where R is independently selected in each instance from hydrogen or alkyl;

R 3 is sulfonyl, acyl, amino, alkyl, heteroalkyl, cycloalkyl, cycloheteroalkyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl, each of which is optionally substituted;

R 4 is hydrogen, halogen, —OH, or —NO 2 , or R 4 is amino, alkoxyl, sulfonyl, acyl, alkyl, heteroalkyl, cycloalkyl, cycloheteroalkyl, aryl, and heteroaryl, each of which is optionally substituted; or R 3 , R 4 , X 2 and the attached nitrogen form an optionally substituted heterocyclyl;

R 5 and R 6 are independently in each instance hydrogen or selected from the group consisting of alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl, each of which is optionally substituted;

Z is

 wherein * indicates the point of attachment; m is 0, 1, or 2;

W 1 and W 2 are in each instance independently selected from the group consisting of optionally substituted alkylene, alkyleneoxy, alkyleneamino, alkylenethio, alkylenesulfoxyl, and alkylenesulfonyl;

W 3 and W 4 are in each instance independently selected from the group consisting of amino, oxygen, alkylene, alkyleneoxy, alkyleneamino, and heteroalkylene, wherein at least one of W 1 or W 2 is oxygen, and wherein when one of W 1 or W 2 is optionally substituted methylene, at least one of W 3 or W 4 is oxygen or alkyleneoxy, and wherein Z does not include a peroxide bond, a sulfenate bond, or a sulfenamide bond;

X 3 is a bond or optionally substituted methylene; and

Y is hydrogen, hydroxyl, or carbonyl, or amino, acyl, sulfonyl, alkyl, or heteroalkyl, each of which is optionally substituted is described; or

Z is

wherein * indicates the point of attachment; n is 1, 2, or 3;

W 1 and W 2 are in each instance independently selected from the group consisting of optionally substituted methylene, oxygen, and amino;

W 3 and W 4 are in each instance independently selected from the group consisting of amino, oxygen, alkylene, and heteroalkylene, wherein at least one of W 1 or W 2 is oxygen, and wherein when one of W 1 or W 2 is optionally substituted methylene, at least one of W 3 or W 4 is oxygen, and wherein Z does not include a peroxide bond, a sulfenate bond, or a sulfenamide bond;

X 3 is a bond or optionally substituted methylene; and

Y is hydrogen, hydroxyl, or carbonyl, or amino, acyl, sulfonyl, alkyl, or heteroalkyl, each of which is optionally substituted.

2. The compound of claim 1 wherein Z is

wherein * indicates the point of attachment.

3. The compound of claim 1 wherein X 3 is a bond.

4. The compound of claim 1 wherein Z is

n is 1 or 2, and W 4 is optionally substituted ethylene or propylene.

5. The compound of claim 1 wherein Z is

n is 1, and W 4 is optionally substituted ethylene.

6. The compound of claim 1 wherein Y is hydrogen.

7. The compound of claim 1 wherein W 1 , W 2 , and W 3 are oxygen.

8. The compound of claim 1 wherein Z is

9. The compound of claim 1 wherein Z is

10. The compound of claim 1 wherein R 1 and R 2 are each hydrogen.

11. The compound of claim 1 wherein R 5 is optionally substituted arylalkyl, X 1 is a bond, R 6 is hydrogen, X 2 is S(O) 2 , R 4 is optionally substituted aryl, and R 3 is iso-butyl.

12. The compound of claim 1 wherein R 3 is optionally substituted arylalkyl.

13. The compound of claim 1 wherein W 2 is oxygen.

14. The compound of claim 1 wherein W 3 or W 4 is oxygen.

15. The compound of claim 1 wherein W 2 and one of W 3 or W 4 is oxygen.

16. The compound of claim 1 wherein W 2 and W 3 are oxygen.

17. The compound of claim 1 wherein each of W 1 , W 2 , and W3 is oxygen.

18. The compound of claim 1 wherein W 1 is optionally substituted methylene.

19. A pharmaceutical composition comprising one or more compounds of claim 1 and further comprising one or more carriers, diluents, or excipients, or a combination thereof for treating HIV infection.

20. A method for treating a patient in need of relieve of an HIV infection, the method comprising the step of administering to a patient in need of relief from the HIV infection a therapeutically effective amount of one or more compounds of claim 1 or a pharmaceutical composition thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 15, 2013
From: GHOSH, ARUN K; XU, CHUN-XIAO; PARHAM, GARTH L
To: PURDUE RESEARCH FOUNDATION
Reel/Frame 030417/0542 →
CONFIRMATORY LICENSE Recorded Apr 12, 2013
From: PURDUE UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 030205/0559 →
Continuity (2)
Provisional Application 61379414 · Sep 2, 2010
Related Publication 20130158094A1 · Jun 20, 2013